AstraZeneca PLC’s Tagrisso (osimertinib) is likely to become the standard of care for patients with unresectable locally advanced stage III EGFR-mutant non-small cell lung cancer (NSCLC) who have undergone chemoradiotherapy, based on Phase III data presented at the American Society of Clinical Oncology annual meeting showing an overwhelming benefit on the primary endpoint of progression-free survival (PFS).
ASCO: AstraZeneca Touts LAURA’s Large PFS Benefit In EGFR-Mutant NSCLC
While the study allowed a crossover, and the overall survival benefit did not reach statistical significance, the drug maker sees the PFS benefit from Tagrisso as likely to drive uptake.
